INTERCEPT PHARMACEUTICALS, INC.·4

Jan 31, 4:04 PM ET

Freedberg Jared 4

4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Jan 31, 2023

Insider Transaction Report

Form 4
Period: 2023-01-27
Freedberg Jared
General Counsel and Secretary
Transactions
  • Award

    Option to Purchase Common Stock

    2023-01-27+20,00020,000 total
    Exercise: $18.40Exp: 2033-01-27Common Stock (20,000 underlying)
  • Award

    Common Stock

    2023-01-27+12,20059,674 total
Footnotes (2)
  • [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023.
  • [F2]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023.

Documents

1 file
  • 4
    tm234878-4_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT